World Market for Psychotherapeutic Drugs Closes in on $50 Billion in Sales

New York, January 22, 2007 — Based on the steadily increasing success of current drugs on the market as well as the potential success of numerous drugs currently in late stage development or awaiting regulatory approval, sales of psychotherapeutic drugs treating everything from schizophrenia and depression to ADHD and anxiety are expected to reach nearly $50 billion by 2010, according to a new report from life science research firm Kalorama Information.

The World Market for Psychotherapeutic Drugs, the most exhaustive guide to this booming market, shows 2005 revenues checking in at $35.7 billion, up 3.9% over 2004. The report anticipates new products bringing in an additional $6.3 billion by 2010 increasing the competitive outlook in many segments.

Antipsychotics and antimanics along with antidepressants make up the lions share of worldwide sales accounting for nearly 80% of the market. Sales of antianxiety drugs, ADHD stimulants and nonstimulants, and other psychotherapeutic drugs segments rounded out the mix of remedies to treat a remarkably under-treated global incidence of mental illness.

In fact, the U.S. accounts for more than 62% of worldwide sales as in many parts of the world there is still a negative view and stigma surrounding mental health issues. In contrast, Japan accounts for only 2% of global sales.

“The potential market is definitely worth billions more than the current market where many regions suffer from a lack of education, mental health policy, and services to evaluate and treat mental health patients,” notes Melissa Elder, the report’s author. “Despite these global inadequacies, there are extremely promising drugs in the pipeline that should have a tremendous impact on this industry within the next few years.”

The World Market for Psychotherapeutic Drugs provides a historical market overview, including condition statistics and market forecasts for each of the major psychotherapeutic segments. It also includes in-depth company profiles of emerging competitors and leaders in the field, and profiles of drugs in the pipeline with expected approval status and implications for their impact on the market. It can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Psychotherapeutic-Drugs-1340128. It is also available at MarketResearch.com.

About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent market research for the life sciences. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit www.KaloramaInformation.com.